These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35220997)

  • 41. Effects of Sleeve Gastrectomy on Nonalcoholic Fatty Liver Disease in an Obese Rat Model.
    Watanabe K; Ohta M; Takayama H; Tada K; Shitomi Y; Kawasaki T; Kawano Y; Endo Y; Iwashita Y; Inomata M
    Obes Surg; 2018 Jun; 28(6):1532-1539. PubMed ID: 29280057
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
    Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
    J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Recent Advances in the Medicinal Chemistry of Farnesoid X Receptor.
    Fang Y; Hegazy L; Finck BN; Elgendy B
    J Med Chem; 2021 Dec; 64(24):17545-17571. PubMed ID: 34889100
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The roles and interaction of FXR and PPARs in the pathogenesis of nonalcoholic fatty liver disease.
    Li YY; Cao CY; Zhou YL; Nie YQ; Cao J; Zhou YJ
    Arab J Gastroenterol; 2020 Sep; 21(3):162-168. PubMed ID: 32451200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation.
    Yao J; Zhou CS; Ma X; Fu BQ; Tao LS; Chen M; Xu YP
    World J Gastroenterol; 2014 Oct; 20(39):14430-41. PubMed ID: 25339829
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies.
    Zhang CH; Zhou BG; Sheng JQ; Chen Y; Cao YQ; Chen C
    Pharmacol Res; 2020 Sep; 159():104984. PubMed ID: 32502637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
    Li X; Wang Z; Klaunig JE
    Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An Intestinal Microbiota-Farnesoid X Receptor Axis Modulates Metabolic Disease.
    Gonzalez FJ; Jiang C; Patterson AD
    Gastroenterology; 2016 Nov; 151(5):845-859. PubMed ID: 27639801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversal of metabolic disorders by pharmacological activation of bile acid receptors TGR5 and FXR.
    Jadhav K; Xu Y; Xu Y; Li Y; Xu J; Zhu Y; Adorini L; Lee YK; Kasumov T; Yin L; Zhang Y
    Mol Metab; 2018 Mar; 9():131-140. PubMed ID: 29361497
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.
    Schumacher JD; Guo GL
    Handb Exp Pharmacol; 2019; 256():325-357. PubMed ID: 31201553
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Farnesoid X receptor: a master regulator of hepatic triglyceride and glucose homeostasis.
    Jiao Y; Lu Y; Li XY
    Acta Pharmacol Sin; 2015 Jan; 36(1):44-50. PubMed ID: 25500875
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Curcumin regulates endogenous and exogenous metabolism via Nrf2-FXR-LXR pathway in NAFLD mice.
    Yan C; Zhang Y; Zhang X; Aa J; Wang G; Xie Y
    Biomed Pharmacother; 2018 Sep; 105():274-281. PubMed ID: 29860219
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Defective FXR-SHP Regulation in Obesity Aberrantly Increases
    Seok S; Sun H; Kim YC; Kemper B; Kemper JK
    Diabetes; 2021 Mar; 70(3):733-744. PubMed ID: 33328206
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The identification of farnesoid X receptor modulators as treatment options for nonalcoholic fatty liver disease.
    Fiorucci S; Biagioli M; Baldoni M; Ricci P; Sepe V; Zampella A; Distrutti E
    Expert Opin Drug Discov; 2021 Oct; 16(10):1193-1208. PubMed ID: 33849361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Emerging role of carboxylesterases in nonalcoholic fatty liver disease.
    Liu J; Yao B; Gao L; Zhang Y; Huang S; Wang X
    Biochem Pharmacol; 2022 Nov; 205():115250. PubMed ID: 36130649
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
    Gai Z; Gui T; Hiller C; Kullak-Ublick GA
    J Biol Chem; 2016 Jan; 291(5):2397-411. PubMed ID: 26655953
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.